Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma

Modern Pathology

Volumn 27, Issue 7, 2014, Pages 1014-1019

  Kuhn, Elisabetta ^a   Bahadirli Talbott, Asli ^a   Shih, Ie Ming ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

amplification; CCNE1; cyclin E1; endometrial intraepithelial carcinoma; FISH; fluorescence in situ hybridization; serous carcinoma

Indexed keywords

CYCLIN E; CYCLIN E1; UNCLASSIFIED DRUG; CCNE1 PROTEIN, HUMAN; ONCOPROTEIN;

ARTICLE; CANCER GROWTH; CCNE1 GENE; COPY NUMBER VARIATION; ENDOMETRIAL INTRAEPITHELIAL CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE IDENTIFICATION; GENE MUTATION; GENOME ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MOLECULAR GENETICS; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; UTERINE SEROUS CARCINOMA; UTERUS CARCINOMA; CYSTADENOCARCINOMA; DISEASE COURSE; ENDOMETRIUM TUMOR; GENE DOSAGE; GENETICS; MUTATION; PATHOLOGY; UTERUS CANCER;

CYCLIN E; CYSTADENOCARCINOMA, SEROUS; DISEASE PROGRESSION; ENDOMETRIAL NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MUTATION; ONCOGENE PROTEINS; UTERINE NEOPLASMS;

EID: 84903776015     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.209     Document Type: Article

References (22)

1. Lee KR, Tavassoli FA, Prat J, et al. Tumors of the ovary and peritoneum. In: Tavassoli FA, Devilee P (eds). World Health Organization Tumours of the Breast and Female Genital System. IARC Press: Lyon, France, 2003, pp 224-225
2. Hamilton CA, Cheung MK, Osann K, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 2006;94: 642-646
3. Kuhn E, Wu RC, Guan B, et al. Genome-wide analyses of uterine serous carcinoma identify pathway aberrations involving cyclinE-Fbxw7, PI3K and p53. J Natl Cancer Inst 2012;104: 1503-1513
4. Zhao S, Choi M, Overton JD, et al. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci USA 2013;110: 2916-2921
5. Cancer Genome Atlas Research NetworkKandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497: 67-73
6. Le Gallo M, O'Hara AJ, Rudd ML, et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet 2012;44: 1310-1315
7. Geisen C, Moroy T. The oncogenic activity of cyclin E is not confined to Cdk2 activation alone but relies on several other, distinct functions of the protein. J Biol Chem 2002;277: 39909-39918
8. Onoyama I, Nakayama KI. Fbxw7 in cell cycle exit and stem cell maintenance: Insight from gene-Targeted mice. Cell Cycle 2008;7: 3307-3313
9. Donnellan R, Chetty R. Cyclin E in human cancers. FASEB J 1999;13: 773-780
10. Natrajan R, Mackay A, Wilkerson PM, et al. Functional characterization of the 19q12 amplicon in grade III breast cancers. Breast Cancer Res 2012;14: R53
11. Kuhn E, Ayhan A, Shih IeM, et al. The pathogenesis of atypical proliferative Brenner tumor: An immunohistochemical and molecular genetic analysis. Mod Pathol; advance online publication, 26 July 2013; doi: 10.1038/modpathol.2013.142 (e-pub ahead of print
12. Kuhn E, Meeker AK, Visvanathan K, et al. Telomere length in different histologic types of ovarian carcinoma with emphasis on clear cell carcinoma. Mod Pathol 2011;24: 1139-1145
13. Varella-Garcia M. Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: The EGFR fluorescence in situ hybridization assay. Diagn Pathol 2006;1: 19
14. Loeb KR, Kostner H, Firpo E, et al. A mouse model for cyclin E-dependent genetic instability and tumorigenesis. Cancer Cell 2005;8: 35-47
15. Spruck CH, Won KA, Reed SI. Deregulated cyclin E induces chromosome instability. Nature 1999;401: 297-300
16. Duensing A, Duensing S. Guilt by association? p53 and the development of aneuploidy in cancer. Biochem Biophys Res Commun 2005;331: 694-700
17. Song H, Hollstein M, Xu Y. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol 2007;9: 573-580
18. Nakayama N, Nakayama K, Shamima Y, et al. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer 2010;116: 2621-2634
19. Etemadmoghadam D, George J, Cowin PA, et al. Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer. PLoS One 2010;5: E15498
20. Kuhn E, Kurman RJ, Vang R, et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions. J Pathol 2012;226: 421-426
21. Kuhn E, Meeker A, Wang TL, et al. Shortened telomeres in serous tubal intraepithelial carcinoma: An early event in ovarian high-grade serous carcinogenesis. Am J Surg Pathol 2010;34: 829-836
22. Kuhn E, Bahadirli-Talbott A, Kurman R, et al. CCNE1 amplification may precede centrosome number abnormality in progression from serous tubal intraepithelial carcinoma to high-grade serous carcinomä . Mod Pathol 2013;26: 283A.